Fate Therapeutics Stock Filter Stocks by Fundamentals
| FATE Stock | USD 2.42 0.13 5.68% |
Fate Therapeutics fundamentals help investors to digest information that contributes to Fate Therapeutics' financial success or failures. It also enables traders to predict the movement of Fate Stock. The fundamental analysis module provides a way to measure Fate Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fate Therapeutics stock.
Fate | Shares Owned by Institutions |
Fate Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Fate Therapeutics from analyzing Fate Therapeutics' financial statements. These drivers represent accounts that assess Fate Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Fate Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 7.5B | 5.5B | 977.0M | 368.1M | 349.7M | |
| Enterprise Value | 1.3B | 7.4B | 5.5B | 1.0B | 429.7M | 408.2M |
Fate Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fate Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fate Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Fate Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Fate Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fate Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fate Therapeutics' value.| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 3.4 M | Baker Bros Advisors Lp | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Assenagon Asset Management Sa | 2024-09-30 | 2.4 M | Goldman Sachs Group Inc | 2024-06-30 | 2.3 M | Geode Capital Management, Llc | 2024-09-30 | 2.3 M | Vestal Point Capital Lp | 2024-06-30 | 2 M | Bank Of America Corp | 2024-06-30 | 2 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | Redmile Group, Llc | 2024-09-30 | 13.2 M | Vanguard Group Inc | 2024-09-30 | 10.4 M |
Fate Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (17.04) % | ||||
| Current Valuation | 62.88 M | ||||
| Shares Outstanding | 113.89 M | ||||
| Shares Owned By Insiders | 2.17 % | ||||
| Shares Owned By Institutions | 97.83 % | ||||
| Number Of Shares Shorted | 15.9 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 19.40 X | ||||
| Revenue | 63.53 M | ||||
| Gross Profit | (224.15 M) | ||||
| EBITDA | (172.23 M) | ||||
| Net Income | (160.93 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 103.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 3.18 X | ||||
| Cash Flow From Operations | (132.26 M) | ||||
| Short Ratio | 12.76 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Target Price | 6.31 | ||||
| Number Of Employees | 181 | ||||
| Beta | 1.88 | ||||
| Market Capitalization | 260.82 M | ||||
| Total Asset | 506.22 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 292.45 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
| Net Asset | 506.22 M |
About Fate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Fate Therapeutics Piotroski F Score and Fate Therapeutics Altman Z Score analysis. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.